Nina Paleologos to Antineoplastic Agents
This is a "connection" page, showing publications Nina Paleologos has written about Antineoplastic Agents.
Connection Strength
0.206
-
Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncol. 2018 04; 7(2):CNS08.
Score: 0.070
-
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 2016 Jan; 126(1):185-192.
Score: 0.061
-
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61.
Score: 0.057
-
Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. 2007 Jul; 9(3):314-8.
Score: 0.008
-
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol. 2006 Apr; 8(2):183-8.
Score: 0.008
-
Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol. 1990 Dec; 28(6):818-22.
Score: 0.003